Thrombosis
Feature
200 cardiovascular drugs now in development
Research interest is strong in heart failure and stroke.
News
EC approves emicizumab for hemophilia A with inhibitors
The European Commission (EC) has granted marketing authorization for emicizumab (Hemlibra®), a bispecific factor IXa- and factor X-directed...
Feature
Thrombectomy’s success treating strokes prompts rethinking of selection criteria
very low number needed to treat for acute ischemic stroke patients to benefit from thrombectomy peaks interest in widening the treatment...
News
Exercise doesn’t offset VTE risk from TV viewing
Getting the recommended amount of physical activity does not eliminate the increased risk of venous thromboembolism (VTE) associated with frequent...
News
Team creates device to study hemostasis
Researchers have engineered a miniature model system for studying hemostasis. They believe the device could serve as a drug discovery platform...
Conference Coverage
JAK inhibitors for RA: Is VTE risk overblown?
MAUI, HAWAII – “Certainly we are seeing these events. The question is, ‘How overdone is this?’ ” said Mark C. Genovese, MD.
News
Product seems effective for ITI in severe hemophilia A
Results of a retrospective study suggest a recombinant factor VIII Fc fusion protein (rFVIIIFc) can be effective for immune tolerance induction (...
News
Product increases FIX levels in hemophilia B
MADRID—The recombinant factor IX (FIX) product CB 2679d/ISU304 can increase FIX levels in patients with severe hemophilia B, according to a phase...
Conference Coverage
Promising outcomes of thrombolysis for caval extension of iliofemoral DVT
CHICAGO – Acute caval involvement predicts reduced risk of postthrombotic syndrome.
News
Factor IX product launched in US
The recombinant, GlycoPEGylated coagulation factor IX product Rebinyn® is now available in the US for the treatment of patients with hemophilia B...